Is TNXP a good stock to buy?
Aria Murphy 
TNXP average analyst rating is Strong Buy. See TNXP analyst rating chart. TNXP average analyst price target ($4.00) is above its current price ($0.69).
How many shares of tonix are there?
Tonix Pharmaceuticals Holding Corp (US:TNXP) has 98 institutional owners and shareholders (aka shareholding pattern) that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 65,655,038 shares.
What does tonix pharmaceuticals make?
About Tonix Pharmaceuticals We are progressing small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions through our CNS portfolio. Our immunology portfolio includes vaccines to prevent infectious diseases and biologics to address immunosuppression, cancer and autoimmune diseases.
When did tonix pharmaceuticals go public?
Tonix also announced that its common stock will begin trading on The NASDAQ Capital Market under the symbol “TNXP” on August 9, 2013.
Will tonix Pharmaceuticals stock go up?
The Tonix Pharmaceuticals Holding Corp. stock price gained 10.84% on the last trading day (Tuesday, 10th Aug 2021), rising from $0.70 to $0.78. , and has now gained 3 days in a row. The price has been going up and down for this period, and there has been a 6.27% gain for the last 2 weeks.
Will Nspr stock go up?
Stock Price Forecast The 1 analysts offering 12-month price forecasts for InspireMD Inc have a median target of 16.50, with a high estimate of 16.50 and a low estimate of 16.50. The median estimate represents a +326.36% increase from the last price of 3.87.
Who owns TNXP stock?
Top 10 Owners of Tonix Pharmaceuticals Holding Corp
| Stockholder | Stake | Shares bought / sold |
|---|---|---|
| The Vanguard Group, Inc. | 4.39% | +12,762,859 |
| Renaissance Technologies LLC | 2.56% | +8,183,200 |
| BlackRock Fund Advisors | 2.30% | +6,113,399 |
| Geode Capital Management LLC | 0.88% | +1,971,887 |
Where is tonix Pharmaceuticals located?
New York City
Tonix Pharmaceuticals (Tonix Pharmaceuticals Holding Corp.) is a pharmaceutical company based in New York City that focuses on repurposed drugs for central nervous system conditions and as of 2020 was also pursuing a vaccine for COVID-19 and a biodefense project.
Why is tonix stock dropping?
After scoring two promising FDA designations on its lead drug, tiny Tonix Pharmaceuticals is aborting its late-stage study in PTSD due to lousy results — nearly flat-lining the company’s stock Friday morning. But once Nasdaq hit the play button, Tonix tanked over 77%.
Who is Tonix Pharmaceuticals and what do they do?
Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) (Tonix) is a clinical-stage biopharmaceutical company committed to discovering and developing innovative and proprietary new therapeutics.
When did Tonix Pharmaceuticals do a reverse split?
Shares of Tonix Pharmaceuticals reverse split before market open on Wednesday, November 28th 2018. The 1-10 reverse split was announced on Tuesday, November 27th 2018. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, November 27th 2018.
What kind of drug is Tonix for PTSD?
TNX-1600 (a triple reuptake inhibitor) is a third product candidate being developed for PTSD, as a daytime treatment. Tonix‘s programs for treating addiction conditions also include TNX-1300** (double-mutant cocaine esterase), which is in Phase 2 development for the treatment of cocaine intoxication.
Who are the major holders of TNXP stock?
TNXP stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, BlackRock Inc., Geode Capital Management LLC, Millennium Management LLC, Citadel Advisors LLC, Northern Trust Corp, HRT Financial LP, and Morgan Stanley.
